Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

98 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox.
Taher AT, Porter JB, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, Siritanaratkul N, Origa R, Karakas Z, Habr D, Zhu Z, Cappellini MD. Taher AT, et al. Among authors: chuncharunee s. Eur J Haematol. 2014 Jun;92(6):521-6. doi: 10.1111/ejh.12270. Epub 2014 Mar 25. Eur J Haematol. 2014. PMID: 24460655 Free PMC article. Clinical Trial.
Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study.
Taher AT, Porter J, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, Siritanaratkul N, Galanello R, Karakas Z, Lawniczek T, Ros J, Zhang Y, Habr D, Cappellini MD. Taher AT, et al. Among authors: chuncharunee s. Blood. 2012 Aug 2;120(5):970-7. doi: 10.1182/blood-2012-02-412692. Epub 2012 May 15. Blood. 2012. PMID: 22589472 Free article. Clinical Trial.
Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients.
Taher AT, Porter JB, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, Siritanaratkul N, Galanello R, Karakas Z, Lawniczek T, Habr D, Ros J, Zhang Y, Cappellini MD. Taher AT, et al. Among authors: chuncharunee s. Am J Hematol. 2013 Jun;88(6):503-6. doi: 10.1002/ajh.23445. Epub 2013 May 13. Am J Hematol. 2013. PMID: 23553596 Free PMC article. Clinical Trial.
Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study.
Taher AT, Porter JB, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, Siritanaratkul N, Galanello R, Karakas Z, Lawniczek T, Habr D, Ros J, Zhu Z, Cappellini MD. Taher AT, et al. Among authors: chuncharunee s. Ann Hematol. 2013 Nov;92(11):1485-93. doi: 10.1007/s00277-013-1808-z. Epub 2013 Jun 18. Ann Hematol. 2013. PMID: 23775581 Free PMC article. Clinical Trial.
Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia.
Taher AT, Porter JB, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, Siritanaratkul N, Origa R, Karakas Z, Habr D, Zhu Z, Cappellini MD. Taher AT, et al. Among authors: chuncharunee s. Br J Haematol. 2015 Jan;168(2):284-90. doi: 10.1111/bjh.13119. Epub 2014 Sep 12. Br J Haematol. 2015. PMID: 25212456 Free article. Clinical Trial.
Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy.
Walewski J, Hellmann A, Siritanaratkul N, Ozsan GH, Ozcan M, Chuncharunee S, Goh AS, Jurczak W, Koren J, Paszkiewicz-Kozik E, Wang B, Singh S, Huebner D, Engert A, von Tresckow B. Walewski J, et al. Among authors: chuncharunee s. Br J Haematol. 2018 Nov;183(3):400-410. doi: 10.1111/bjh.15539. Epub 2018 Aug 30. Br J Haematol. 2018. PMID: 30168134 Free article. Clinical Trial.
Patient preference for deferasirox film-coated versus dispersible tablet formulation: a sequential-design phase 2 study in patients with thalassemia.
Viprakasit V, Hamdy MM, Hassab HMA, Sherief LM, Al-Bagshi M, Khattab M, Chuncharunee S, Dung PC, Küpesiz A, Shekhawat A, Sonawane Y, Perez LT, Slader C, Taher AT. Viprakasit V, et al. Among authors: chuncharunee s. Ann Hematol. 2023 Aug;102(8):2039-2049. doi: 10.1007/s00277-023-05240-3. Epub 2023 May 25. Ann Hematol. 2023. PMID: 37227493 Free PMC article. Clinical Trial.
Effect of genotype on pulmonary hypertension risk in patients with thalassemia.
Teawtrakul N, Ungprasert P, Pussadhamma B, Prayalaw P, Fucharoen S, Jetsrisuparb A, Pongudom S, Sirijerachai C, Chansung K, Wanitpongpun C, Chuncharunee S. Teawtrakul N, et al. Among authors: chuncharunee s. Eur J Haematol. 2014;92(5):429-34. doi: 10.1111/ejh.12261. Epub 2014 Jan 30. Eur J Haematol. 2014. PMID: 24400859
98 results